skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies

Review

(2707) Views  (1478) Full article downloads

Authors: Christina Voulgari, Dimitrios Papadogiannis, Nicholas Tentolouris

Published Date October 2010 Volume 2010:6 Pages 883 - 903
DOI: http://dx.doi.org/10.2147/VHRM.S11681

Christina Voulgari, Dimitrios Papadogiannis, Nicholas Tentolouris
First Department of Propaedeutic and Internal Medicine, Athens University Medical School, Laiko General Hospital, Athens, Greece

Abstract: Diabetic cardiomyopathy (DCM), although a distinct clinical entity, is also a part of the diabetic atherosclerosis process. It may be independent of the coexistence of ischemic heart disease, hypertension, or other macrovascular complications. Its pathological substrate is characterized by the presence of myocardial damage, reactive hypertrophy, and intermediary fibrosis, structural and functional changes of the small coronary vessels, disturbance of the management of the metabolic cardiovascular load, and cardiac autonomic neuropathy. These alterations make the diabetic heart susceptible to ischemia and less able to recover from an ischemic attack. Arterial hypertension frequently coexists with and exacerbates cardiac functioning, leading to the premature appearance of heart failure. Classical and newer echocardiographic methods are available for early diagnosis. Currently, there is no specific treatment for DCM; targeting its pathophysiological substrate by effective risk management protects the myocardium from further damage and has a recognized primary role in its prevention. Its pathophysiological substrate is also the objective for the new therapies and alternative remedies.

Keywords: cardiovascular disease, atherosclerosis, cardiac autonomic neuropathy, echocardiography, treatment strategies






Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Practical recommendations for treatment of hypertension in older patients
Cardiac risk stratification: Role of the coronary calcium score
Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization
Benefits of statin therapy and compliance in high risk cardiovascular patients
New class of agents for treatment of hypertension: Focus on direct renin inhibition
Effect of vascular burden as measured by vascular indexes upon vascular dementia: a matched case-control study
New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil
Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University